Imatinib 'highly effective' at treating CML in most patients

Snyder, David; Harris, Jason; Shafer, Emily
July 2008
Hem/Onc Today;7/25/2008, Vol. 9 Issue 13, p27
The article discusses research being done on the effectiveness of imatinib in treating chronic myeloid leukemia (CML). It references a study published in the 2008 issue of the "Journal of Oncology." The study included 204 adults who were diagnosed with CML and were placed under imatinib treatment regimen for six months. Researchers found that overall survival rate reached 83.2 percent in patients who received imatinib. They concluded that imatinib-treated patients will live longer compared to those treated with earlier therapies.


Related Articles

  • A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours. Wolf, Dominik; Rumpold, Holger // Drug Safety;2009, Vol. 32 Issue 11, p1001 

    Targeting constitutively activated tyrosine kinases, such as BCR-ABL, in chronic myeloid leukaemia (CML) and c-KIT in gastrointestinal stromal tumours (GIST) has substantially changed the clinical management of both diseases. The introduction of imatinib, a tyrosine kinase inhibitor mainly...

  • DASISION: Dasatinib superior to imatinib in newly diagnosed CML. Harris, Jason; Lawrence, Leah; Southall, Jennifer // Hem/Onc Today;6/25/2010, Vol. 11 Issue 12, p35 

    The article discusses research study on the response of patients with newly diagnosed chronic myeloid leukemia to dasatinib treatment, published in "The New England Journal of Medicine."

  • Nilotinib linked to fewer BCR-ABL mutations in chronic phase CML. Adams, Stacey L.; Leiser, Mark; Shafer, Emily; Taliercio, Adam; Volansky, Rob // Hem/Onc Today;4/25/2013, Vol. 14 Issue 8, p44 

    The article discusses the results of a study which showed a link between nilotinib and fewer treatment-emergent breakpoint cluster region-abelson (BCR-ABL) mutations than imatinib in chronic myeloid leukemia treatment and reduced rates of progression to accelerated phase.

  • Therapy Options in Imatinib Failures. Ramirez, Pablo; DiPersio, John F. // Oncologist;Apr2008, Vol. 13 Issue 4, p424 

    Chronic myelogenous leukemia (CML) is defined by the presence of the constitutively active tyrosine kinase breakpoint cluster region/Abelson (Bcr-Abl), which activates numerous signal transduction pathways leading to uncontrolled cell proliferation. The development of the Bcr-Abl-targeted...

  • CHRONIC MYELOID LEUKAEMIA IN HUSM IN THE ERA OF TARGETED THERAPY. Dzarr A., Abu; Hassan, Rosline; P., Thanaseelan; Ghazali, Selamah; AlwI, Zilfahlil; Ankathil, Ravindran; Husin, Azlan; Baba, Abdul Aziz // Malaysian Journal of Medical Sciences;Jan2007 Supplement, Vol. 14, p100 

    Introduction: The Philadelphia chromosome, a genetic abnormality involving reciprocal transfer of ABL genes at chromosome 9q31-34 with BCR region at chromosome 22q has been recognized since the 1960's. The introduction of imatinib mesylate (Glivec) which inhibits the over expressed tyrosine...

  • Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Hochhaus, A.; Müller, M. C.; Radich, J.; Branford, S.; Kantarjian, H. M.; Hanfstein, B.; Rousselot, P.; Kim, D.-W.; Lipton, J. H.; Bleickardt, E.; Lambert, A.; Hughes, T. P.; Müller, M C // Leukemia (08876924);Sep2009, Vol. 23 Issue 9, p1628 

    Dasatinib is a highly potent BCR-ABL inhibitor that has shown durable efficacy in patients with chronic phase (CP) chronic myeloid leukemia (CML) after resistance, suboptimal response, or intolerance to prior imatinib. In patients with CML, BCR-ABL transcript measurement is the most sensitive...

  • Efficacy of nilotinib, dasatinib confirmed for CML in chronic phase. Shafer, Emily // Hem/Onc Today;7/10/2008, Vol. 9 Issue 12, p14 

    The article discusses research being done on the treatment of chronic myelogenous leukemia (CML). It references a study by M. U. Mauro et al and another study by H. M. Kantarjan et al which both examine the effectiveness of nilotinib and dasatinib in treating patients with chronic-phase CML....

  • Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL. Breccia, Massimo; Alimena, Giuliana // Current Drug Targets;Jun2009, Vol. 10 Issue 6, p530 

    Imatinib mesylate is currently the standard therapy for chronic myeloid leukemia (CML) patients. Despite the remarkable results achieved with imatinib, the emergence of resistance to this drug has become a significant problem. Several strategies have been developed to overcome imatinib...

  • Chronic myeloid leukemia. Savoie, Lynn // Oncology Exchange;May2014, Vol. 13 Issue 2, p25 

    The article reports on a research finding from a multicenter stop imatinib trial for chronic-phase chronic myeloid leukemia (CML). Noted is that it is possible to discontinue imatinib among chronic myeloid leukemia patients who had deep molecular response (DMR). Results indicate an occurrence of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics